Výsledky vyhledávání - Yi‐Long Wu
- Zobrazuji výsledky 1 - 20 z 233
- Přejít na další stránku
-
1
-
2
-
3
-
4
-
5
-
6
-
7
Overcoming immune evasion with innovative multi-target approaches for glioblastoma Autor Hai Su, Peng Yin, Yi‐Long Wu, Xiaoli Zeng
Vydáno 2025Revisão -
8
-
9
-
10
Emerging therapies for non-small cell lung cancer Autor Chao Zhang, Natasha B. Leighl, Yi‐Long Wu, Wen‐Zhao Zhong
Vydáno 2019Revisão -
11
-
12
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection Autor Yi‐Long Wu, Roy S. Herbst, Helen Mann, Yuri Rukazenkov, Marcelo Marotti, Masahiro Tsuboi
Vydáno 2018Artigo -
13
-
14
-
15
-
16
-
17
Multiple primary malignancies involving lung cancer Autor Feng Li, Wen‐Zhao Zhong, Feiyu Niu, Ning Zhao, Jin‐Ji Yang, Hong‐Hong Yan, Yi‐Long Wu
Vydáno 2015Artigo -
18
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy Autor Bruno Coudert, Tudor‐Eliade Ciuleanu, K. Park, Yi‐Long Wu, Giuseppe Giaccone, Wolfram Brugger, P. Gopalakrishna, Federico Cappuzzo
Vydáno 2011Artigo -
19
Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IU... Autor Saulius Cicėnas, Sarayut Lucien Geater, Petar Petrov, Yevhen Hotko, Gregory Hooper, Fan Xia, Nadejda Mudie, Yi‐Long Wu
Vydáno 2016Artigo -
20
Vyhledávací nástroje:
Související témata
Medicine
Internal medicine
Oncology
Cancer
Lung cancer
Biology
Chemotherapy
Epidermal growth factor receptor
Cancer research
Gefitinib
Confidence interval
Genetics
Erlotinib
Pathology
Gene
Hazard ratio
Immunotherapy
Clinical endpoint
Adenocarcinoma
Cisplatin
Randomized controlled trial
Clinical trial
Gastroenterology
Environmental health
Population
Adverse effect
Paleontology
Osimertinib
Surgery
Malignant pleural effusion